Discovery of Di- and Trihaloacetamides as Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity
Chunlong Ma(University of Arizona), Jun Wang(Rutgers Sexual and Reproductive Health and Rights), Julia A. Townsend(University of Arizona), Janice Jang(University of Arizona), Juliana Choza(University of Arizona), Yanmei Hu(University of Arizona), Maura V. Gongora(University of South Florida), Yan Xiang(Sichuan University), Haozhou Tan(Rutgers, The State University of New Jersey), Fushun Zhang(The University of Texas at San Antonio Health Science Center), Michael T. Marty(University of Arizona), Yu Chen(University of South Florida), Zilei Xia(University of Arizona), Xiangzhi Meng(University of California, Los Angeles), Xiujun Zhang(University of South Florida), M. Sacco(University of South Florida)
Cited by 155
Related Papers
Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against M <sup>pro</sup> and cathepsin L
|Science Advances|2020|400
Clofazimine broadly inhibits coronaviruses including SARS-CoV-2
|Nature|2021|216
Discovery of SARS-CoV-2 Papain-like Protease Inhibitors through a Combination of High-Throughput Screening and a FlipGFP-Based Reporter Assay
|ACS Central Science|2021|200
The <i>in vitro</i> antiviral activity of lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by targeting the heparan sulfate co-receptor
|Emerging Microbes & Infections|2021|190
Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors
|Journal of Medicinal Chemistry|2021|168